Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience

Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience have?

Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience has 23 citations in the OpenAlex counts ScholarIQ stores.

When was Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience published?

Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience has 2019 year in the ScholarIQ index.

What is the open-access status of Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience?

Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience has closed oa status in the ScholarIQ index.

What is the DOI of Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience?

The DOI for Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience is on the source record.

What is the PMID of Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience?

The PMID for Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience is on the source record.

What is the OpenAlex record for Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience?

The OpenAlex for Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience is on the source record.